SFM
INZY

Sphera Funds Management’s Inozyme Pharma INZY Stock Holding History

Sphera Funds Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,191,140
Closed -$1.08M – 119
2025
Q1 		$1.08M Hold
1,191,140
– – 0.25% 88
2024
Q4 		$3.3M Hold
1,191,140
– – 0.6% 64
2024
Q3 		$6.23M Sell
1,191,140
-271,584
-19% -$1.41M 0.99% 35
2024
Q2 		$6.52M Buy
1,462,724
+89,817
+7% +$435K 0.89% 37
2024
Q1 		$10.5M Sell
1,372,907
-190,000
-12% -$1.04M 1.48% 25
2023
Q4 		$6.66M Buy
1,562,907
+328,000
+27% +$1.17M 1.07% 35
2023
Q3 		$5.19M Buy
1,234,907
+102,940
+9% +$524K 0.94% 37
2023
Q2 		$6.31M Sell
1,131,967
-649,891
-36% -$3.84M 0.98% 38
2023
Q1 		$10.2M Buy
1,781,858
+156,800
+10% +$414K 1.71% 16
2022
Q4 		$1.71M Buy
1,625,058
+450,000
+38% +$786K 0.37% 44
2022
Q3 		$3.15M Buy
1,175,058
+9,458
+0.8% +$34.2K 0.44% 49
2022
Q2 		$5.56M Buy
+1,165,600
New +$5.07M 0.59% 29
2020
Q4 		– Sell
-196,411
Closed -$5.16M – 120
2020
Q3 		$5.16M Buy
+196,411
New +$4.88M 0.51% 60

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Sphera Funds Management's INZY Position: Q2 2025 in Review

Sphera Funds Management sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 1,191,140 shares — an estimated $1.08M sold.

Sphera Funds Management first reported a position in INZY in Q3 2020 and held it in 13 quarters. The position peaked at $10.5M in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Sphera Funds Management reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Sphera Funds Management sold 1,191,140 Inozyme Pharma shares in Q2 2025, an estimated $1.08M.
  • Sphera Funds Management first reported a position in Inozyme Pharma in Q3 2020 and held it in 13 quarters.
  • Sphera Funds Management's Inozyme Pharma position peaked at $10.5M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.